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Abstract
Purpose The purpose of the study was to assess the preva-
lence of pulmonary embolism (PE) and other lung diseases
among pregnant women with suspected PE and to calculate
the radiation exposure to patient and fetus in this population.
As a secondary aim, we evaluated the negative predictive
value of a normal ventilation/perfusion single photon emis-
sion computed tomography (V/P SPECT) examination in
pregnancy.
Methods We studied all 127 pregnant women who had
suspected PE and had undergone V/P SPECTat our institution
in the course of a 5-year period. Radiation exposure to patient
and fetus and the negative predictive value of a normal V/P
SPECT examination were also measured.
Results V/P SPECT identified PE in 11 women (9 %).
Moreover, in 15 women (12 %) the examination revealed
pneumonia (in 2 cases in addition to PE) and in 1 woman
signs of airway obstruction were revealed. Among the 116/
127 women (91 %) where PE was ruled out by V/P SPECT,
none was diagnosed subsequently with PE or deep venous
thrombosis (DVT) during the same pregnancy or puerperal
period. For P SPECT, the calculated fetal absorbed dose was
<0.6 mGy,and the calculated breast absorbed dose 0.6 mGy.
For V SPECT, the calculated fetal absorbed dose was<
0.014 mGy and the breast absorbed dose 0.25 mGy.
Conclusion The prevalence of PEwas low (9%) among preg-
nant women with suspected disease. Pneumonia was diag-
nosed in 12 % of patients. The negative predictive value of
V/P SPECT was high, and the radiation exposure from V/P
SPECTwas low both for fetus and patient.
Keywords Pregnancy . Pulmonary embolism . V/P SPECT .
Radiation exposure
Introduction
The risk for pulmonary embolism (PE) is increased about
fivefold during pregnancy and the puerperal period [1, 2]
due to both changes in the coagulation system and mechanical
factors such as vein compression, and more than 50 % of
events occur in the first 20 weeks of pregnancy [3]. As clinical
symptoms are unspecific, it is important to take into account
the possibility of PE when a pregnant woman experiences
symptoms such as chest pain, dyspnoea, pyrexia, tachycardia,
leg pain and swelling (particularly in the left leg) or lower
abdominal pain. However, many of these symptoms may be
due to the physiological stress of pregnancy or to other car-
diopulmonary diseases, such as pneumonia or on rare occa-
sions left heart failure. In the initial diagnostic evaluation of
PE, testing of clinical probability is important, but few of the
test algorithms have been evaluated during pregnancy [4]. D-
dimer is usually increased during pregnancy, and therefore
current evidence does not support the use of negative D-
dimer to rule out PE in a pregnant woman [5]. Therefore, a
clinical suspicion of PE always needs to be confirmed by an
imaging test. Currently, ventilation/perfusion single photon
emission computed tomography (V/P SPECT) [6, 7] or planar
pulmonary scintigraphy [8] is recommended by different
European guidelines as an initial imaging modality, based on
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its low radiation exposure, high sensitivity and specificity and
possibility for follow-up. The American Society of Thoracic
Radiology [9] also recommends planar pulmonary scintigra-
phy as the preferred imaging method during pregnancy.
We studied all pregnant women who underwent V/P
SPECT at our institution for suspected PE over a 5-year peri-
od. The primary aims of the study were to assess the preva-
lence of PE and other lung diseases and to calculate the radi-
ation exposure to patient and fetus in this population. As a
secondary aim, we evaluated the negative predictive value of
a normal V/P SPECT examination in pregnancy.
Materials and methods
In the course of a 5-year period (2009–2013), 127 pregnant
women (mean age 30 years, range 18–48) were referred for
examination with V/P SPECT due to suspected PE at Skåne
University Hospital, Lund, Sweden. During the study period,
30 patients (24 %) were examined in the first trimester (weeks
1–15), 59 (46 %) in the second trimester (weeks 16–27) and
38 (30 %) in the third trimester (weeks 28–40). In accordance
with the European guidelines [6, 7], the 2-day protocol was
implemented during the first trimester of pregnancy: P SPECT
only on the first day and V SPECT performed the next day
only if indicated (Table 1). Chest X-ray was performed only if
considered clinically indicated. Patient files from all hospitals
in the region were checked for potential later PE or deep
venous thrombosis (DVT) diagnoses made in the 127 women
during the same pregnancy and puerperal period. Clinical
characteristics and symptoms at presentation in the 127 wom-
en are shown in Table 2.
Absorbed dose calculation
Breast doses were calculated using data from ICRP 53 and
ICRP 80 [10, 11] and fetal doses were calculated according to
Russell et al. [12]. The 99mTc-Technegas was not assumed to
cross over to the placenta, which means that the only contri-
bution to the fetal dose is the radiation from activity within the
lungs of the mother. The specific absorbed fractions for pho-
tons were obtained from www.doseinfo-radar.com, accessed
on 23 Apr 2014, and were recalculated to the photon energy
for 99mTc (140 keV). The 99mTc-Technegas was assumed to
remain within the lungs until complete decay as no biological
excretion of the radiopharmaceutical occurs.
Perfusion (P) SPECT
P SPECTwas performed in accordance with the guidelines of
the European Association for NuclearMedicine (EANM) [6, 7]
with a dual-head gamma camera in the supine position, after i.v.
administration of 50 MBq 99mTc-macroaggregated albumin
(MAA, TechneScan LyoMAA®, Mallinckrodt Medical,
Petten, The Netherlands).
Ventilation (V) SPECT
V SPECT was performed after inhalation of aerosolized
99mTc-Technegas® (Cyclomedica Ltd, Lucas Heights, NSW,
Australia), reaching 30 MBq in the lungs. The procedure was
carried out with the patient in the supine position over a period
of 11 min (10 s per stop, 64 stop for each camera) as described
elsewhere [13].
V/P SPECT protocol
The 1-day protocol for V/P SPECT started with inhalation of
up to 30 MBq 99mTc-Technegas to the lung. V SPECT was
performed in the supine position, with acquisition lasting
11 min. Without changing the patient position, P SPECT
followed immediately, after i.v. injection of 120 MBq 99mTc-
MAA, with acquisition lasting 5 min. The methodology has
been described in full elsewhere [13, 14]. Over the same 5-
Table 1 Different examination techniques used in 127 pregnant
women undergoing V/P SPECT for suspected PE
Trimester Patients P SPECT V SPECT V/P SPECT
1st (weeks 1–15) 30 14 13 3
2nd (weeks 16–27) 59 6 1 52
3rd (weeks 28–40) 38 38
Data shown separately for women in each trimester of pregnancy
Table 2 Clinical characteristics and symptoms at presentation [n (%)]
in 127 pregnant women undergoing V/P SPECT for suspected PE
Clinical characteristics n (%)
Previous VTE 6 (5)
Family history of VTE 12 (9)
Pneumonia 7 (6)
Bronchial asthma or chronic obstructive pulmonary disease 8 (6)
Pulmonary histiocytosis 1 (1)
Cystic fibrosis 1 (1)
Pre-eclampsia 1 (1)
Symptoms




High fever 2 (2)
Haemoptysis 6 (5)
Swollen leg 7 (6)
VTE venous thromboembolism
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year period, 61 pregnant women with suspected PE were ex-
amined with multidetector CT (MDCT), 37 (61 %) of
them during the night or weekends when V/P SPECT
was not available.
Statistics and ethics
The study is a descriptive analysis, which had been approved
by the local Ethics Committee of Lund University.
Results
PE was identified using V/P SPECT in 11 (9 %) of the 127
patients. The extent of PE was small to medium, not exceed-
ing 40 % of the pulmonary vascular bed in any case.
Moreover, in 15 patients (12 %) the examination revealed
pneumonia [7] (in 2 of these cases in addition to PE), and in
1 patient it indicated signs of airway obstruction, defined in
[15] (Table 3). Among the 30 patients examined during the
first trimester, PE was diagnosed in 5. In this group, 14 pa-
tients underwent P SPECT only and only 1 in this group was
diagnosed with PE, whereas 13 patients underwent V SPECT
the next day and among them 4 were diagnosed with PE, 1
with concomitant pneumonia. In four patients pneumonia was
observed as the sole finding. Among patients examined during
the second trimester, 4 of 59 were diagnosed with PE. Six
patients underwent P SPECT only and none was positive for
PE. One more patient needed a V SPECT the next day which
showed findings typical for pneumonia. Among 52 other pa-
tients undergoing the 1-day V/P SPECT protocol 4 were di-
agnosed with PE, 1 with concomitant pneumonia (Fig. 1) that
was also clinically treated. Moreover, one woman was diag-
nosed with airway obstruction.
Among those examined during the last trimester, 3 of 38
women were diagnosed with PE, 1 of whom also had pneu-
monia. In four other women, signs of pneumonia were ob-
served. Among the 116 of 127 patients (91 %) in whom PE
was ruled out by V/P SPECT, none was diagnosed with PE or
DVT during the same pregnancy or the puerperal period. A
negative study was thus 100 % predictive of no clinically
apparent emboli in this time period.
Calculated breast absorbed doses were 0.2 mGy after inha-
lation of 30 MBq of 99mTc-Technegas and 0.6 mGy after in-
travenous injection of 120 MBq 99mTc-MAA. If only P
SPECT was performed calculated breast absorbed dose was
0.25mGy [10–12]. The doses to the fetus were calculated to
the stage of gestation (Table 4) [10–12].
Multidetector computed tomography
Among pregnant women undergoing MDCT during the 5-
year period, 3 of 61 showed signs of PE. In two of these, the
examination was not considered as optimal. However, six pa-
tients showed parenchymal changes, and in six other cases the
examination was reported by the radiologist as inconclusive
and not allowing exclusion of PE. One patient underwent two
MDCT examinations that were both considered inconclusive.
Among 127 pregnant women, 7 were suspected for DVT. Five
were examined with ultrasound, and only one was
pathological.
Discussion
This is the first study reporting the value of V/P SPECT during
pregnancy. It established that we were able to follow the
European guidelines [6, 7] and use the proposed 2-day proto-
col for PE diagnosis in the first trimester of pregnancy in the
majority of women in this group. Moreover, V/P SPECTwas
demonstrated to be a safe procedure regarding sensitivity, neg-
ative predictive value and radiation exposure to the fetus and
the pregnant woman. All reports were diagnostic. P SPECT
alone was sufficient in 20 patients and identified women in
whom it was necessary to perform the additional V SPECT to
confirm or exclude PE and comorbidity. Furthermore, V
SPECT helped to clarify the cause of symptoms by identifying
additional diagnoses of pneumonia and chronic obstructive
pulmonary disease (COPD). The majority of our patients thus
benefited from V SPECT.
The prevalence of PE among pregnant women with
suspected disease was highest during the first trimester,
confirming results from other investigators [2]. However, the
prevalence of PE in our study during the entire pregnancy was
9 %, which is higher than presented by others [16, 17]. The
reason for this may be that previous investigators might have
underestimated the true incidence either by not sending pa-
tients for imaging tests or alternatively by relying on MDCT
which in the PIOPED II study [18] showed a comparably low
sensitivity for PE diagnosis in the general population.
Furthermore, Ridge et al. reported a high number of non-
diagnostic findings onMDCT during pregnancy and therefore
Table 3 Results of P and V SPECT in 127 pregnant women
undergoing V/P SPECT for suspected PE
Trimester
1 2 3
PE 11 (9%) 5 4 2
Pneumonia 15 (12%) 4 6 5
Left heart failure 1 (<1%) 1
Airway obstruction 1 (<1%) 1
Results shown both in total and separately for women in each trimester of
pregnancy
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considered pulmonary planar scintigraphy more reliable [19].
Use of planar pulmonary scintigraphy as recommended by
some guidelines [8, 9] is still often applied in many clinics
although it is clearly less sensitive than V/P SPECT [20–23].
In this retrospective study, no V/P SPECT examination in
pregnancy was not diagnostic, in contrast to the inconclusive
results in 6 of the 61 (10%) women undergoingMDCT during
the same period. Such a good performance is in line with other
studies that have evaluated V/P SPECT for PE diagnosis in
larger cohorts of non-pregnant patients [22, 24–27].
The debate regarding the preferred method of PE diagnosis
in pregnancy is still ongoing. Guidelines in general recom-
mend pulmonary scintigraphy as a first choice method [6, 8,
9]. However, American guidelines [9] recommend an MDCT
if the chest X-ray is pathological. This is probably because
planar scintigraphy traditionally has been used by the majority
of institutions until now. The results of this study of pregnant
patients and other studies in patients with suspected PE in
general showed that a pathological X-ray is not a contraindi-
cation to the use of V/P SPECT. European guidelines, by
contrast, recommend pulmonary SPECT as a first choice re-
gardless of pathological chest X-ray [6].
In addition to sensitivity, one important reason supporting
the use of V/P SPECT in pregnancy is safety, both for the fetus
and the pregnant woman. The measured breast absorbed dose
with V/P SPECT was 0.8 mGy in our study. This is a low
Fig. 1 Frontal (a) and sagittal (b)
slices from V/P SPECT and chest
X-ray in a pregnant woman
diagnosed with both PE and
pneumonia in the second
trimester of pregnancy. Red
arrows indicate segmental
perfusion defects in areas with
preserved ventilation representing
PE in the right and left lung. Blue
arrows indicate absent ventilation
and reduced perfusion
representing pneumonia in the
lower left lung
Table 4 Fetal absorbed dose (mGy) calculated to the stage of gestation after i.v. injection of 99mTc-MAA and inhalation of 99mTc-Technegas in 127
pregnant women undergoing V/P SPECT for suspected PE




Absorbed dose after 120
MBq 99mTc-MAA
Early 0.14 0.007 0.34
3 months 0.20 0.007 0.48
6 months 0.25 0.011 0.60
9 months 0.20 0.014 0.48
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figure in comparison to calculated breast absorbed doses of
20–50 mGy reported for MDCT [28–33]. Fetal absorbed
doses, on the other hand, are similar for MDCT and V/P
SPECT [29].
When choosing a diagnostic method, it is always important
to assess its negative predictive value. None of the women in
whom the P SPECTor V/P SPECT examination was negative
for PE was diagnosed with PE or DVT later during the same
pregnancy or the following puerperal period, confirming that
the method performs well also in this respect. The V/P SPECT
examination is thus a fast, safe and reliable way of excluding
PE in this important patient group.
Conclusion
This study showed that among pregnant women with
suspected disease the incidence of a positive scan suggesting
PE is low (9%), reaffirming the need for low radiation doses.
The negative predictive value of V/P SPECT was high, and
the radiation exposure from V/P SPECTwas low, both for the
fetus and the patient. Aventilation study was helpful to clarify
patient symptoms and might be cost-effective regarding time
and need for other examinations.
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